Assembly Biosciences Announces Effective Date of Reverse Stock Split
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market under the same symbol (ASMB) when the market opens on February 12, 2024, with the new CUSIP number 045396207.
Related news for (ASMB)
- Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
- Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
- New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
- Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
- Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights